Involvement of Val762Ala Polymorphism in the Onset of Cervical Cancer in Caucasian Women by unknown
ORIGINAL RESEARCH ARTICLE
Involvement of PARP-1 Val762Ala Polymorphism in the Onset
of Cervical Cancer in Caucasian Women
Andrzej Roszak • Margarita Lianeri •
Anna Sowin´ska • Paweł P. Jagodzin´ski
Published online: 1 May 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Background and Objective Data on the Val762Ala
(rs1136410) polymorphism in the poly(adenosine diphos-
phate [ADP]-ribose) polymerase 1 (PARP-1) gene as a risk
factor for various types of cancers in different ethnicities
are inconsistent. We studied this association in a Caucasian
population.
Methods Using high-resolution melting curve analysis
(HRM), we studied the distribution of the PARP-1
Val762Ala polymorphism in patients with cervical cancer
(n = 446) and in controls (n = 491).
Results Logistic regression analysis adjusting for age,
pregnancy, oral contraceptive use, tobacco smoking,
and menopausal status demonstrated that the PARP-1
Val762Ala polymorphism was associated with an increased
risk of cervical cancer. The adjusted odds ratio (OR) for
patients with the Ala/Val genotype versus the Val/Val geno-
type was 1.381 (95 % CI = 1.025–1.859, p = 0.033), and the
adjusted OR for the Ala/Ala or Ala/Val genotype versus the
Val/Val genotype was 1.403 (95 % CI = 1.057–1.863,
p = 0.019). The p value from the chi-square test of the trend
observed for the PARP-1 Val762Ala polymorphism was sta-
tistically significant (ptrend = 0.0123). Stratified analyses of
the PARP-1 Val762Ala genotype distribution and cervical
cancer risk showed that the age-adjusted OR of Ala/Ala or
Ala/Val vs Val/Val for pregnancy was 1.388 (95 % CI =
1.027–1.877, p = 0.0328), 1.773 (95 % CI = 1.145–2.745,
p = 0.0100) for contraceptive use, and 1.604 (95 % CI =
1.132–2.272, p = 0.0077) for postmenopausal women. The
age-adjusted OR of Ala/Val vs Val/Val for contraceptive use
was 1.769 (95 % CI = 1.114–2.809, p = 0.0154) and for
postmenopausal women was 1.577 (95 % CI = 1.094–2.272,
p = 0.0143).
Conclusion Our studies suggest that the PARP-1
Val762Ala polymorphism may be a genetic risk factor for
cervical cancer.
1 Introduction
The development of cervical tumors is a multi-step process
including infection by the human papillomavirus (HPV)
and involvement of the immune system, tumor suppressor
genes, and proto-oncogenes [1, 2]. During cervical
tumorigenesis, the normal cervical epithelium is trans-
formed into cervical intraepithelial neoplasia (CIN), which
may further progress to invasive cervical carcinoma [1, 2].
It is well recognized that the primary etiologic factors of
this cancer are some oncogenic HPVs in which E6 and E7
oncoproteins deregulate innate and adaptive immunity and
abnormally alter apoptosis, causing the cell cycle to drive
normal cervical epithelium cells to immortalization [2–4].
The oncoproteins E6 and E7 may also result in chromo-
somal instability and increase DNA damage during HPV
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carcinogenesis [3, 5]. Moreover, DNA damage is accu-
mulated during DNA replication as well as through expo-
sure to genotoxic cellular metabolites and environmental
insults [6]. There are several canonical pathways for DNA
repair, and the predominant pathway for single strand break
repair is the base excision repair (BER) pathway [7, 8]. The
BER may cooperate with a family of related enzymes
termed poly(adenosine diphosphate [ADP]-ribose)
polymerases (PARP) [9, 10]. Approximately 90 % of the
cellular PARP activity is due to PARP-1, which is an early-
activated sensor of DNA strand breakage [6, 11]. PARP-1
conducts extensive polymerization of ADP-ribose from its
substrate nicotinamide adenine dinucleotide (NAD?) to
nuclear proteins involved in DNA repair, genomic stability,
transcription regulation, cell death, and proliferation [12,
13]. The proteins involved in pathways of DNA repair are
crucial in the prevention of cancer development, and
numerous single nucleotide polymorphisms (SNPs) in
genes encoding these proteins may be risk factors for
various cancers [14, 15]. At least 60 SNPs have been
reported in PARP-1 (http://snp500cancer.nci.nih.gov), and
among them is the most frequently studied functional
PARP-1 polymorphism, which includes a 2446T[C tran-
sition leading to Val762Ala variation [16, 17].
Data demonstrating that the PARP-1 Val762Ala
(rs1136410) substitution is a risk factor for various types of
cancers in different ethnicities are inconsistent [16, 17].
Recently, the contribution of the PARP-1 Val762Ala
polymorphism to cervical cancer was demonstrated in an
Asian population [18]. We evaluated the PARP-1
Val762Ala genotype and allele frequencies in patients with
cervical cancer (n = 446) and controls (n = 491) from a
Polish population.
2 Patients and Methods
2.1 Patients and Controls
The patients were 446 women with histologically recognized
cervical carcinoma according to the International Federation
of Gynecology and Obstetrics (FIGO). All women were
enrolled between April 2007 and Jun 2012 at the Department
of Radiotherapy, Greater Poland Cancer Center in Poznan,
Poland (Table 1). The controls included 491 unrelated healthy
female volunteers who were matched by age to the patients
(Table 1). Data on pregnancy, oral contraceptive use, tobacco
smoking, and menopausal status were obtained during the
clinical interview. All individuals were Caucasian, enrolled
from the Wielkopolska (Greater Poland) area of Poland.
Patients and controls provided written informed consent. The
study was approved by the Local Ethical Committee of Poz-
nan University of Medical Sciences.
2.2 Genotyping
DNA was isolated from peripheral leucocytes using a
salting-out procedure. The PARP-1 Val762Ala (rs1136410)
DNA fragment was amplified using the primers 50 CTATC
ATCAGACCCTCCCCTGA 30 and 50 GATACCTAAGTC
GGGGGCTTTC 30. This polymorphism was then geno-
typed by high-resolution melting curve analysis (HRM) on
a LightCycler 480 system (Roche Diagnostics, Mannheim,
Germany). The presence of the PARP-1 Val762Ala poly-
morphism was verified by commercial sequencing analysis
of 15 % randomly selected samples.
Table 1 Clinical and demographic characteristics of the patients and
controls
Characteristic Patients Controls
(n = 446) (n = 491)
aMean age (years) ± SD 52.5 ± 9.9 51.8 ± 10.1
Tumor stage
IA 59 (13.2 %)
IB 61 (13.7 %)
IIA 59 (13.2 %)
IIB 53 (11.9 %)
IIIA 146 (32.7 %)
IIIB 52 (11.7 %)
IVA 9 (2.0 %)
IVB 7 (1.6 %)
Histological grade
G1 85 (19.1 %)
G2 141 (31.6 %)
G3 96 (21.5 %)
Gx 124 (27.8 %)
Histological type
Squamous cell carcinoma 376 (84.3 %)
Adenocarcinoma 54 (12.1 %)
Other 16 (3.6 %)
Pregnancy
Never 47 (10.5 %) 54 (11.0 %)
Ever 399 (89.5 %) 437 (89.0 %)
Oral contraceptive pill use
Never 244 (54.7 %) 275 (56.0 %)
Ever 202 (45.3 %) 216 (44.0 %)
Tobacco smoking
Never 289 (64.8 %) 328 (66.8 %)
Ever 157 (35.2 %) 163 (33.2 %)
Menopausal status
Premenopausal 155 (34.8 %) 186 (37.9 %)
Postmenopausal 291 (65.2 %) 305 (62.1 %)
HPV genotypes
16 and 18 307 (68.8 %)
16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68
346 (77.6 %)
a Age at first diagnosis
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2.3 Statistical Analysis
The differences in genotypic and allelic prevalences
between patients and controls and their genotype devia-
tions from Hardy–Weinberg (HW) equilibrium were eval-
uated via the chi-square test. The polymorphism was tested
for association with cervical cancer incidence using the
chi-square test for trend (ptrend). Moreover, the odds ratio
(OR) and 95 % confidence intervals (95 % CI) were cal-
culated. Unconditional logistic regression analysis was
used to adjust for the effects of confounders such as age,
pregnancy, oral contraceptive use, tobacco smoking, and
menopausal status. A p value of \0.05 was considered
statistically significant.
3 Results
3.1 Prevalence of the PARP-1 Val762Ala
Polymorphism in Women with Cervical Cancer
The distribution of PARP-1 Val762Ala genotypes did not
exhibit significant differences from HW equilibrium in the
cases and controls. The prevalence and adjusted analyses
of PARP-1 Val762Ala genotypes in women with cervical
cancer are presented in Table 2. The frequency of the
PARP-1 Ala/Ala genotype was approximately 1.7-fold
higher in the patients than in the controls. The PARP-1
Ala/Val heterozygous genotype frequency was also higher
in women with cervical cancer than in the controls(0.29
and 0.23, respectively). The PARP-1 Ala allele frequency
was increased in patients compared to controls (0.19 and
0.15, respectively). The p value from the chi-square test
of the trend observed for the PARP-1 Val762Ala poly-
morphism was statistically significant (ptrend = 0.0123).
Logistic regression analysis demonstrated that the PARP-1
Val762Ala polymorphism was associated with an increased
risk of cervical cancer. The adjusted OR for patients with
the Ala/Val genotype versus the Val/Val genotype was
1.381 (95 % CI = 1.025–1.859, p = 0.033) and the
adjusted OR for the Ala/Ala or Ala/Val genotype versus
the Val/Val genotype was 1.403 (95 % CI = 1.057–1.863,
p = 0.019). However, we did not observe statistical sig-
nificance for the Ala/Ala genotype versus the Val/Val
genotype. In this case, the adjusted OR was 1.290 (95 %
CI = 0.922–1.804, p = 0.136). Stratification of the patients
based on the histological type of the cancer revealed a
borderline association of the Ala/Ala or Ala/Val genotype
with squamous cell carcinoma, with an adjusted OR of
1.340 (95 % CI = 1.068–1.804, p = 0.048). However, we
did not find a significant association between the PARP-1
Val762Ala polymorphism and adenocarcinoma, tumor
stage, or histological grade (data not shown).
3.2 Stratified Analyses of PARP-1 Val762Ala
Genotype and Cervical Cancer Risk
The results of age-adjusted analyses of PARP-1 Val762Ala
genotype and cervical cancer risk stratified by pregnancy,
oral contraceptive use, tobacco smoking, and menopausal
status are presented in Table 3. An increase in cervical
cancer risk was seen among patients with a positive history
of pregnancy or oral contraceptive use, and among women
of postmenopausal age. The adjusted OR for pregnancy
with Ala/Ala or Ala/Val vs Val/Val genotype was 1.388
(95 % CI = 1.027–1.877, p = 0.0328). The adjusted OR
for contraceptive use with Ala/Val vs Val/Val genotype
was 1.769 (95 % CI = 1.114–2.809, p = 0.0154) and with
Ala/Ala or Ala/Val vs Val/Val genotype it was 1.773
(95 % CI = 1.145–2.745, p = 0.0100). The adjusted OR
for postmenopausal women with Ala/Val vs Val/Val
genotype was 1.577 (95 % CI = 1.094–2.272, p = 0.0143)
and with Ala/Ala or Ala/Val vs Val/Val genotype it was
1.604 (95 % CI = 1.132–2.272, p = 0.0077). However, no
significant association was seen between PARP-1
Val762Ala and patients with a positive history of tobacco
smoking.
Table 2 Association of the PARP-1 Val762Ala (rs1136410) polymorphism with cervical cancer
Genotype Patients (frequency) Controls (frequency) Odds ratio (95 % CI) pa Adjusted pa ptrend
Odds ratio (95 % CI)b
Val/Val 295 (0.66) 361 (0.74) Reference – Reference
Ala/Val 129 (0.29) 114 (0.23) 1.385 (1.031–1.860) 0.0304 1.381 (1.025–1.859) 0.033 0.0123
Ala/Ala 22 (0.05) 16 (0.03) 1.683 (0.8677–3.263) 0.1199 1.290 (0.922–1.804) 0.136
Ala/Val ? Ala/Ala 151 (0.34) 130 (0.26) 1.421 (1.074–1.882) 0.0138 1.403 (1.057–1.863) 0.019
Minor allele frequency 0.19 0.15
a Chi-square analysis. bORs were adjusted for age, pregnancy, oral contraceptive use, tobacco smoking, and menopausal status. Significant
results are highlighted in bold
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4 Discussion
The activity of PARP has been implicated in cancer
development and anticancer therapy [16, 17, 19–21].
Efficient DNA repair mechanisms are essential for pro-
tecting against the accumulation of genetic defects in DNA
and subsequent carcinogenesis [14]. It was demonstrated
that Epstein–Barr virus-immortalized lymphocytes from
centenarians displayed a maximal PARP activity that was
significantly higher than that seen in controls aged 20–70
[21]. A large difference between patients with cancer and
healthy subjects in the PARP levels of peripheral blood
mononuclear cells (PBMC) has also been reported [20–24].
Ranjit et al. [20] found that PBMC from patients with
esophageal cancer, breast cancer, and lymphocytic malig-
nancies contained lower levels of PARP than PBMC from
healthy individuals. Furthermore, decreased PARP-1
activity in peripheral blood lymphocytes has been observed
in patients with tumors of the larynx, lung, colon, and
prostate [22–24]. In addition to these findings, skewed
PARP-1 levels have been observed in different primary
human malignancies, including breast, colorectal and head
and neck cancers, and in melanoma [25–27].
The role of the PARP-1 enzyme in tumorigenesis has
also been well documented in the murine model [28–30].
PARP-1 knockout mice (PARP-1-/-) treated with either
alkylating compound or c-radiation exhibited increased
genomic instability, higher numbers of chromosomal
aberrations, and reduced telomere length as compared to
the wild-type mice [28]. The PARP-1-/- mice also dis-
played an increased risk of chemically induced carcino-
genesis of the lung, liver, and colon [29, 30].
Table 3 Stratified analyses of the PARP-1 Val762Ala genotype distribution and cervical cancer risk: pregnancy, oral contraceptive use, tobacco
smoking, and menopausal status
High risk exposure Patients Controls Adjusted odds ratio
(95 % CI)b
pd
Genotype Val/Val Ala/Val Ala/Ala Val/Val Ala/Val Ala/Ala
Pregnancy
Ever 268 114 17 324 101 12 1.363 (0.994–1.868)a 0.0538
1.277 (0.872–1.868) 0.2078
1.388 (1.027–1.877)c 0.0328




Ever 131 60 11 165 44 7 1.769 (1.114–2.809)a 0.0154
1.454 (0.888–2.383)b 0.1355
1.773 (1.145–2.745)c 0.0100




Ever 101 47 9 119 39 5 1.413 (0.849 –2.351)a 0.1812
1.582 (0.890–2.810)b 0.1159
1.528 (0.943–2.475)c 0.0836




Premenopausal 112 36 7 138 42 6 1.048 (0.622–1.768)a 0.8584
1.234 (0.700–2.174)b 0.4649
1.080 (0.660–1.769)c 0.7572
Postmenopausal 183 93 15 223 72 10 1.577 (1.094–2.272)a 0.0143
1.317 (0.869–1.995)b 0.1925
1.604 (1.132–2.272)c 0.0077
a (Ala/Val vs Val/Val); b(Ala/Alal vs Val/Val); c(Ala/Alal and Ala/Val vs Val/Val), dchi-square analysis. All p-values were adjusted for age.
Significant results are highlighted in bold
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Therefore, genetic variants of PARP-1 that contribute to
PARP-1 activity may be risk factors for cancer develop-
ment and progression. The PARP-1 762Ala gene variant
seems to play a protective role in the development of some
cancers in Caucasian populations [31–35], but the opposite
is seen in Chinese populations, where the PARP-1 762Ala
gene variant seems to be a risk factor for cancer in several
studies [36–39].
We found an association of the PARP-1 Ala/Val geno-
type together with the Ala/Ala genotype with cervical
cancer development in Caucasian women, but this associ-
ation was not observed solely for the PARP-1 Ala/Ala
genotype. The PARP-1 Val762Ala polymorphism has also
been recognized as a risk factor for cervical tumorigenesis
in Chinese women [18]. Ye et al. [18] demonstrated that
the PARP-1 Ala/Ala genotype contributed to cervical car-
cinoma but not to CIN. The lack of an association of the
Ala/Ala genotype with cervical cancer in our studies might
due to a lower frequency of the Ala/Ala genotype in
Caucasian women as compared to Chinese women.
Many genetic studies have been performed to date to
assess the role of the PARP-1 Val762Ala polymorphism as
a risk factor for carcinomas of the brain, head and neck,
esophagus, lung, breasts, stomach, bladder, colorectum,
prostate, skin, among others; however, those studies pro-
vide discordant results [22, 31–43]. Recently, two meta-
analyses were conducted to evaluate the contribution of the
PARP-1 Val762Ala polymorphism to overall cancer risk
and the risks of different cancer types in distinct ethnicities
[16, 17]. In the first meta-analysis, the PARP-1 Ala variant
demonstrated an association with an increased risk of
cancer among Asian populations, but a decreased risk of
cancer among Caucasian populations, especially for glioma
[16]. The second meta-analysis confirmed that the PARP-1
Ala variant is associated with a significantly increased risk
of gastric carcinoma in Chinese populations; in Caucasians,
the Ala variant protected significantly from brain tumors in
two American subgroups, but not from the development of
other cancers [17].
The PARP-1 Val762Ala substitution is situated in the
sixth helix of the C-terminal catalytic domain that binds
NAD? and results in poly(ADP-ribosyl)ation [44]. This
C-terminal catalytic domain is currently targeted for the
development of effective PARP inhibitors [45]. The PARP-1
762Ala gene variant is significantly associated with low
poly(ADP-ribosyl) activity [22]. The Val762Ala substitution
in the PARP-1 enzyme produces a steric alteration in the
catalytic domain leading to reduced activity of the PARP-1
762Ala enzyme variant [46].
In our studies, we also observed that PARP-1 Val762Ala
increased the risk of cervical cancer in women with a
positive history of pregnancy, oral contraceptive use, and
postmenopausal women. This is in agreement with
literature indicating possible causative roles in cervical
tumorigenesis of contraceptive use, tobacco consumption,
age, and environmental exposures [47–49]. These con-
founding variables, especially exposure to unknown envi-
ronmental insults, may affect the evaluation of genetic
factors, including the PARP-1 Val762Ala SNP, as risk
factors for various cancers [47–49]. The two recent meta-
analyses indicate that the PARP-1 Val762Ala substitution
may contribute to not only race-specific but also tissue-
specific genetic effects in tumorigenesis [16, 17]. Our
findings demonstrate the association of the PARP-1 762Ala
gene variant with cervical cancer in Caucasians. This may
be due to interactions between the reduced activity of the
PARP-1 Ala variant enzyme and individual exposure to
some environmental factors. In addition to our findings, the
PARP-1 Ala/Ala and Val/Ala genotypes have been shown
to be risk factors for bladder cancer in a large cohort of
Caucasian patients [50]. Moreover, in Caucasians, the
PARP-1 Ala/Ala genotype was also significantly associated
with an increased risk of prostate cancer [22].
Our genetic assessment is the first to demonstrate that
the PARP-1 762Ala gene variant can be a risk factor for
cervical cancer in a Caucasian cohort; this study should
therefore be replicated in other independent cohorts.
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